Seres Therapeutics (MCRB) PT Set at $16.00 by Oppenheimer

Seres Therapeutics (NASDAQ:MCRB) has been assigned a $16.00 price target by equities researchers at Oppenheimer in a research note issued on Friday. The firm currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price target indicates a potential upside of 80.18% from the company’s previous close.

A number of other equities analysts have also commented on the stock. BidaskClub lowered shares of Seres Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 20th. Chardan Capital initiated coverage on shares of Seres Therapeutics in a research report on Monday, October 22nd. They set a “buy” rating and a $15.00 target price on the stock. ValuEngine lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 17th. Bank of America lowered shares of Seres Therapeutics from a “neutral” rating to an “underperform” rating in a report on Friday, August 3rd. Finally, Zacks Investment Research raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $13.81.

Shares of NASDAQ:MCRB opened at $8.88 on Friday. The company has a market cap of $311.27 million, a PE ratio of -4.02 and a beta of 0.61. Seres Therapeutics has a one year low of $5.64 and a one year high of $11.35. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.76 and a current ratio of 2.76.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.03. Seres Therapeutics had a negative net margin of 264.31% and a negative return on equity of 256.24%. Sell-side analysts anticipate that Seres Therapeutics will post -2.41 earnings per share for the current year.

In other Seres Therapeutics news, insider Roger Pomerantz sold 12,518 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The shares were sold at an average price of $9.10, for a total value of $113,913.80. Following the completion of the sale, the insider now directly owns 218,799 shares in the company, valued at $1,991,070.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider John G. Aunins sold 14,279 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $5.94, for a total transaction of $84,817.26. Following the completion of the sale, the insider now owns 103,811 shares of the company’s stock, valued at $616,637.34. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,634 shares of company stock valued at $526,006. 37.10% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Seres Therapeutics during the second quarter worth $117,000. Northern Trust Corp lifted its stake in shares of Seres Therapeutics by 6.0% during the second quarter. Northern Trust Corp now owns 246,310 shares of the biotechnology company’s stock worth $2,118,000 after buying an additional 14,021 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Seres Therapeutics by 18.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock worth $1,009,000 after buying an additional 18,562 shares during the period. Bank of America Corp DE lifted its stake in shares of Seres Therapeutics by 175.0% during the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock worth $314,000 after buying an additional 23,222 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Seres Therapeutics by 6.4% during the third quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock worth $3,199,000 after buying an additional 25,287 shares during the period. Institutional investors own 77.92% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Featured Article: Earnings Per Share (EPS)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply